Curing Disease through Restored Homeostasis

In a strategic alliance, Graviton has joined forces with Ovid Therapeutics to accelerate the development of novel ROCK2 inhibitors, targeting the treatment of Cerebral Cavernous Malformations (CCMs) and orphan CNS indications. We are charged with advancing these promising candidates through Phase 2 clinical trials. Upon completion, Ovid will spearhead the commercialization efforts, delivering this drug to those affected by CCMs and other orphan CNS diseases. 

Graviton has a long-term partnership with the Chinese pharmaceutical company Sino Biopharmaceutical. Sino Biopharmaceutical is working with Graviton on ROCK2 inhibitors. ROCK2 is involved in several diseases including fibrotic, autoimmune and CNS diseases. The company’s plan is to move forward in clinical programs with further investigation in 2024.

Sanofi has made a pivotal equity investment in Graviton Bioscience, forging a dynamic partnership aimed at propelling our innovative selective ROCK2 inhibitors to new heights. This investment is designed to be a long-term engagement, exploring multiple therapeutic areas, particularly within immunology and metabolic syndromes. Together, we are dedicated to enhancing treatment options and improving patient outcomes across the globe.